loading page

Intralesional Bleomycin for Treatment of a Recalcitrant Wart in an Immunocompromised Patient: A Safe, Effective, and Underutilized Therapy
  • +1
  • Tracy Ngo,
  • Hannah Hwang,
  • Bijal Amin,
  • Steven Cohen
Tracy Ngo
Albert Einstein College of Medicine

Corresponding Author:[email protected]

Author Profile
Hannah Hwang
Montefiore Medical Center
Author Profile
Bijal Amin
Montefiore Medical Center
Author Profile
Steven Cohen
Albert Einstein College of Medicine
Author Profile


Injectable bleomycin is infrequently used for recalcitrant warts despite its efficacy, acceptable safety profile, and high patient satisfaction compared to other treatment modalities. We present an immunocompromised patient with a large recalcitrant wart successfully treated with intralesional bleomycin to provide greater clinical exposure, training, and practice with intralesional bleomycin.
22 Sep 2021Submitted to Clinical Case Reports
24 Sep 2021Assigned to Editor
24 Sep 2021Submission Checks Completed
03 Oct 2021Reviewer(s) Assigned
19 Jan 2022Review(s) Completed, Editorial Evaluation Pending
19 Jan 2022Editorial Decision: Accept
Mar 2022Published in Clinical Case Reports volume 10 issue 3. 10.1002/ccr3.5613